Such an asialo‐EPO does not promote the maturation of red blood cells, and thus cannot be abused for doping, but exerts neuroprotective and anti‐apoptotic functions, and therefore could be beneficial in stroke treatment without the potential thromboembolic risk of EPO (Kaneko et al., 2013; Sirén et al., 2009). The gene discussed is EPO; the disease is Stroke.